Tovinontrine for Heart Failure
(Cycle-2-PEF Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you stay on stable doses of your current heart failure medications for at least 4 weeks before and during the screening period, with no planned changes after joining the study.
What data supports the effectiveness of the drug Tovinontrine for heart failure?
What is the purpose of this trial?
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
Research Team
Gail Berman
Principal Investigator
Senior VP Head, Clinical Development Cardurion
Eligibility Criteria
This trial is for adults over 18 with chronic heart failure who have symptoms like shortness of breath or fatigue, signs such as swelling or lung crackles, and a recent history of heart-related hospital visits. They must have certain levels of NT-proBNP in their blood and be on stable heart medication without changes planned post-randomization.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tovinontrine or placebo to evaluate safety and effectiveness in lowering NT-proBNP
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Tovinontrine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cardurion Pharmaceuticals, Inc.
Lead Sponsor